Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 83, 2023 - Issue 2
Submit an article Journal homepage
90
Views
0
CrossRef citations to date
0
Altmetric
Articles

Correlation of serum-soluble mesothelin-related protein, HMGB1 and CA125 in diffuse malignant peritoneal mesothelioma and their combined measurement for prognosis

Lianfen Wanga Department of Gastroenterology, Cangzhou Central Hospital, Hebei, ChinaCorrespondence[email protected]
,
Xuesong Wangb Department of Anorectal Surgery, Cangzhou Central Hospital, Hebei, China
,
Ningning Suna Department of Gastroenterology, Cangzhou Central Hospital, Hebei, China
&
Baosheng Chenc Department of General Surgery, Cangzhou Central Hospital, Hebei, China
Pages 74-78 | Received 22 Aug 2022, Accepted 10 Jan 2023, Published online: 27 Jan 2023

References

  • Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl. Lung Cancer Res. 2018;7(5):537–542.
  • Attanoos RL, Churg A, Galateau-Salle F, et al. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018;142(6):753–760.
  • Hung YP, Dong F, Torre M, et al. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol. 2020;33(11):2269–2279.
  • Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018;31(6):659–669.
  • Carlson B, Harmath C, Turaga K, et al. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol. 2022;47(5):1725–1740.
  • Wei F, Zheng G, Song H, et al. Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2020;38(5):321–326.
  • Döngel İ, Akbaş A, Benli İ, et al. Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. Turk Gogus Kalp Dama. 2019;27(3):374–380.
  • Bruno F, Baratti D, Martinetti A, et al. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: a preliminary study. Eur J Surg Oncol. 2018;44(6):792–798.
  • Deraco M, Kusamura S, Martinetti A, et al. Serum mesothelin as a circulating marker of diffuse malignant peritoneal mesothelioma: preliminary study. EJSO. 2018;44(10):e3.
  • Wang Y, Jiang Z, Yan J, et al. HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma. Dis Markers. 2019;2019:4183157.
  • Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018;22(3):263–277.
  • Yang C, Wu J, Ma J, et al. Significance of combined detection of serum SMRP and CA125 in the diagnosis of malignant peritoneal mesothelioma. Chin J Prim Med Pharm. 2015;24:3709–3711.
  • Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2013;137(5):647–667.
  • Yang H, Xu D, Schmid RA, et al. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol. 2020;12:1758835920971421.
  • Okabe K. Imaging evaluation of local tumor growth in malignant pleural mesothelioma: What is the role of imaging modalities in curative intent surgery for mesothelioma? Malignant pleural mesothelioma. Cham, Switzerland: Springer; 2021. p. 197–205.
  • Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–1693.
  • Takahashi K, Shibukawa T, Moriyama M, et al. Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer—a study on 674 patients. Jpn J Surgery. 1986;16:305–310.
  • Gao R, Wang F, Wang Z, et al. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: an updated meta-analysis. Medicine. 2019;98:e14979.
  • Mencoboni M, Taveggia P, Simonassi CF, et al. Screening issues in exposed subjects and early diagnosis. Mesothelioma. Cham, Switzerland: Springer; 2019. p. 35–43.
  • Tseng Y-J, Huang C-E, Wen C-N, et al. Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. Int J Med Inform. 2019;128:79–86.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.